Johnson & Johnson $JNJ Stock Position Lessened by Mirabella Financial Services LLP

Mirabella Financial Services LLP trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 74.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,660 shares of the company’s stock after selling 16,448 shares during the period. Mirabella Financial Services LLP’s holdings in Johnson & Johnson were worth $868,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth approximately $48,000. Vermillion & White Wealth Management Group LLC lifted its position in Johnson & Johnson by 66.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after purchasing an additional 150 shares during the period. Finally, Pandora Wealth Inc. bought a new position in Johnson & Johnson during the 1st quarter valued at $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. UBS Group upped their price target on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Barclays raised their target price on shares of Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a report on Tuesday. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $203.15.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $201.92 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $207.81. The firm’s 50 day simple moving average is $194.05 and its 200-day simple moving average is $175.25. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market cap of $486.48 billion, a P/E ratio of 19.49, a price-to-earnings-growth ratio of 2.26 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. Johnson & Johnson’s payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.